|
1.
|
2009/09
|
|
Philadelphia chromosome-positive acute myeloid leukemia (Ph + AML) treated with imatinib mesylate (IM): a report with IM plasma concentration and bcr-abl transcripts.
|
|
2.
|
2009/04
|
|
Transformation from follicular lymphoma to high-grade B-cell lymphoma/leukemia with additional t(2;8)(p12;q24), with inverse expressions of c-MYC and BCL-2, and light-chain switch.
|
|
3.
|
2021/03
|
|
Preclinical characterisation and development of a novel myelodysplastic syndrome-derived cell line.
|
|
4.
|
2021/01
|
|
Clonal hematopoiesis in adult pure red cell aplasia.
|
|
5.
|
2021/01
|
|
DHODH inhibition synergizes with DNA-demethylating agents in the treatment of myelodysplastic syndromes
|
|
6.
|
2020/12
|
|
Syk facilitates phagosome-lysosome fusion by regulating actin-remodeling in complement- mediated phagocytosis.
|
|
7.
|
2020/11
|
|
Efficacy of the novel tubulin polymerization inhibitor PTC-028 for myelodysplastic syndrome.
|
|
8.
|
2020/11
|
|
Expert consensus regarding standardization of sample preparation for clotting time assays.
|
|
9.
|
2019/08
|
|
Binimetinib, a novel MEK1/2 inhibitor, exerts anti-leukemic effects under inactive status of PI3Kinase/Akt pathway.
|
|
10.
|
2019/07
|
|
Serum ferritin levels at diagnosis predict prognosis in patients with low blast count myelodysplastic syndromes.
|
|
11.
|
2019/05
|
|
The augmented expression of the cytidine deaminase gene by 5-azacytidine predicts therapeutic efficacy in myelodysplastic syndromes.
|
|
12.
|
2018/08
|
|
An MDS-derived cell line and a series of its sublines serve as an in vitro model for the leukemic evolution of MDS.
|
|
13.
|
2018/06
|
|
Utility of a Fluorescence Microscopy Imaging System for Analyzing the DNA Ploidy of Pathological Megakaryocytes Including 5q- Syndrome
|
|
14.
|
2018/05
|
|
Chronological color change of albumin products
|
|
15.
|
2018/05
|
|
Present status and perspective of laboratory hematology in Japan: On the standardization of blood cell morphology including myelodysplasia: On behalf of the Japanese Society for Laboratory Hematology.
|
|
16.
|
2018/02
|
|
Kinetics of donor-derived anti-HBe antibodies after transfusion
|
|
17.
|
2018
|
|
KIF20A, highly expressed in immature hematopoietic cells, supports the growth of HL60 cell line.
|
|
18.
|
2018
|
|
SIRT1 Activation Disrupts Maintenance of Myelodysplastic Syndrome Stem and Progenitor Cells by Restoring TET2 Function.
|
|
19.
|
2017/08
|
|
Oxidative stress-induced JNK/AP-1 signaling is a major pathway involved in selective apoptosis of myelodysplastic syndrome cells by withaferin-A.
|
|
20.
|
2017/05
|
|
Validation of the revised International Prognostic Scoring System in patients with myelodysplastic syndrome in Japan: results from a prospective multicenter registry.
|
|
21.
|
2017/02
|
|
Certification system for hematopoietic stem cell transplantation based on electronic medical chart and automated blood type compatibility testing systems
|
|
22.
|
2017/02
|
|
Transient false-positive HIV screening test result in a lung cancer patient presumably due to transfusion
|
|
23.
|
2016/09
|
|
Commitment of a hospital transfusion committee to improving use of albumin by switching hypertonic albumin products to a lower formulation
|
|
24.
|
2016/09
|
|
Withaferin A suppresses the growth of myelodysplasia and leukemia cell lines by inhibiting cell cycle progression.
|
|
25.
|
2016/07
|
|
Low neutrophil alkaline phosphatase score is a new aspect of calreticulin-mutated myeloproliferative neoplasms
|
|
26.
|
2016/03
|
|
Prognostic significance of Wilms tumor 1 mRNA expression levels in peripheral blood and bone marrow in patients with myelodysplastic syndromes.
|
|
27.
|
2015/11
|
|
Five-aza-2'-deoxycytidine-induced hypomethylation of cholesterol 25-hydroxylase gene is responsible for cell death of myelodysplasia/leukemia cells.
|
|
28.
|
2015/11
|
|
Fluctuation in Plasma 5-Fluorouracil Concentration During Continuous 5-Fluorouracil Infusion for Colorectal Cancer
|
|
29.
|
2015/10
|
|
Analysis of heredirary elliptocytosis with decreased binding of eosin-5-maleimide to red blood cells
|
|
30.
|
2015/03
|
|
Rigosertib induces cell death of a myelodysplastic syndrome-derived cell line by DNA damage-induced G2/M arrest
|
|
31.
|
2014/11
|
|
Delayed false elevation of circulating tacrolimus concentrations after cord blood transplantation in a patient with myelodysplastic syndrome.
|
|
32.
|
2014/09
|
|
Arsenic disulfide-triggered apoptosis and erythroid differentiation in myelodysplastic syndrome and acute myeloid leukemia cell lines.
|
|
33.
|
2014/07
|
|
Recent status and data analysis of examination for Mycobacterium tuberculosis-specific interferon-gamma release assay, QuantiFERON (QFT)test
|
|
34.
|
2014/01
|
|
An MDS xenograft model utilizing a patient-derived cell line.
|
|
35.
|
2014/01
|
|
Rab27a is essential for the formation of neutrophil extracellular traps (NETs) in neutrophil-like differentiated HL60 cells.
|
|
36.
|
2013/02
|
|
Effects of DNA methyltransferase inhibitors (DNMTIs) on MDS-derived
cell lines
|
|
37.
|
2013/02
|
|
Interference by Pralidoxime (PAM) Salts in Clinical Laboratory Tests
|
|
38.
|
2013
|
|
Clinical evaluation of WT1 mRNA expression levels in peripheral blood and bone marrow in patients with myelodysplastic syndromes.
|
|
39.
|
2012/12
|
|
Rituximab for managing acquired hemophilia A in a case of chronic neutrophilic leukemia with the JAK2 kinase V617F mutation.
|
|
40.
|
2012/10
|
|
Differences in blast immunophenotypes among disease types in myelodysplastic syndromes: a multicenter validation study.
|
|
41.
|
2012/10
|
|
Phase I/II study of decitabine in patients with myelodysplastic syndrome: A multi-center study in Japan.
|
|
42.
|
2012/09
|
|
Marked upregulation of Survivin and Aurora-B kinase are associated with disease progression in the myelodysplastic syndromes.
|
|
43.
|
2012/07
|
|
Editorial (as the Executive Guest Editor): New treatment strategy of the myelodysplastic syndromes.
|
|
44.
|
2012/07
|
|
Utility of DNA methyltransferase inhibitors for the treatment of myelodysplastic syndromes.
|
|
45.
|
2012/06
|
|
Persistent thrombocytosis in elderly patients with rare hyposplenias that mimic essential thrombocythemia.
|
|
46.
|
2012/05
|
|
Morphologic analysis in myelodysplastic syndromes with del(5q) treated with lenalidomide.
|
|
47.
|
2012/03
|
|
Rab27b regulates c-kit expression by controling the secretion of stem cell factor.
|
|
48.
|
2011/11
|
|
Assessment of the severity of organophosphate (fenitrothion) poisoning based on its serum concentration and clinical parameters.
|
|
49.
|
2011/08
|
|
Clinical utility of the neutrophil distribution pattern obtained using the CELL-DYN SAPPHIRE hematology analyzer for the diagnosis of myelodysplastic syndrome.
|
|
50.
|
2011/05
|
|
5q-syndrome in Japan.
|
|
51.
|
2011/02
|
|
Rab27a negatively regulates phagocytosis by prolongation of the actin-coating stage around phagosomes.
|
|
52.
|
2011/01
|
|
Genome-wide identification of human microRNAs located in leukemia-associated genomic alterations.
|
|
53.
|
2011/01
|
|
The impact of serum soluble interleukin-2 receptor levels on the diagnosis of malignant lymphoma.
|
|
54.
|
2010/09
|
|
Multicenter phase II trial of vitamin K2 monotherapy and vitamin K2 plus 1a-hydroxyvitamin D3 combination therapy for low-risk myelodysplastic syndromes.
|
|
55.
|
2010/08
|
|
Prognostic significance of WT1 mRNA and anti-WT1 antibody levels in peripheral blood in patients with myelodysplastic syndromes.
|
|
56.
|
2010/04
|
|
Lenalidomide induces cell death in an MDS-derived cell line with deletion of chromosome 5q by inhibition of cytokinesis.
|
|
57.
|
2010/03
|
|
Acute lymphoblastic leukemia (ALL) with t(8;14)(q11.2;q32) in an elderly patient.
|
|
58.
|
2009/10
|
|
Lenalidomide is active in Japanese patients with symptomatic anemia in low- or intermediate-1 risk myelodysplastic syndromes with a deletion 5q abnormality
|
|
59.
|
2009/07
|
|
ATP-induced osteoclast function: the formation of sealing-zone like structure and the secretion of lytic granules via microtubule-deacetylation under the control of Syk.
|
|
60.
|
2008/10
|
|
High-resolution whole genome tiling path array CGH analysis of CD34+ cells from patients with low-risk myelodysplastic syndromes reveals cryptic copy number alterations and predicts overall and leukemia-free survival.
|
|
61.
|
2008/10
|
|
Myelodysplastic syndrome with chromosome 5 abnormalities: a nationwide survey in Japan.
|
|
62.
|
2008/09
|
|
Validation of the revised 2008 WHO diagnostic criteria in 75 suspected cases of myeloproliferative neoplasm.
|
|
63.
|
2008/07
|
|
Successful treatment of meningoencephalitis caused by methicillin-resistant Staphylococcus aureus with intravenous linezolid in an allogeneic cord blood stem cell transplant recipient
|
|
64.
|
2008/03
|
|
DNA ploidy and cell cycle analyses in the bone marrow cells of patients with megaloblastic anemia using laser scanning cytometry.
|
|
65.
|
2008
|
|
An Attempt of the Practice of Clinical Chemistry Using the Problem-Solving Theme Practice
|
|
66.
|
2007
|
|
A prospective study of cyclosporine A treatment of patients with low-risk myelodysplastic syndrome: presence of CD55-CD59- blood cells predicts platelet response.
|
|
67.
|
2007
|
|
Induction of apoptosis by epigallocatechin-3-gallate in human lymphoblastoid B cells.
|
|
68.
|
2006/05
|
|
Insufficient filling of vacuum tubes as a cause of microhemolysis and elevated serum lactate dehydrogenase levels. Use of a data-mining technique in evaluation of questionable laboratory test results.
|
|
69.
|
2006
|
|
Protein-tyrosine kinase Syk is required for pathogen engulfment in complement-mediated phagocytosis.
|
|
70.
|
2005/03
|
|
Protein-tyrosine kinase, Syk, is required for CXCL12-induced polarization of B cells.
|
|
71.
|
2005
|
|
Improved Detection of Minimal Acute Myeloid Leukemia Cells by the Use of the Combined Parameters of XE-2100 Hematology Analyzer
|
|
72.
|
2005
|
|
Lysosome is a primary organelle in B cell receptor-mediated Apoptosis: an indispensable role of Syk in lysosomal function.
|
|
73.
|
2005
|
|
Myelodysplastic syndromes: Approaches to these disorders difficult to understand.
|
|
74.
|
2003/10
|
|
Effects of Tyrosine Kinase Inhibitor, Imatinib Messylate on a Bcr-Abl-Positive Cell Line: Suppression of the Autonomous Cell Growth but No Effect on the Decreased Adhesive Property and Morphological Changes.
|
|
75.
|
2003/09
|
|
Cyclosporin A therapy for patients with myelodysplastic syndrome: multicenter pilot studies in Japan.
|
|
Display 5 items
|
|
Display all(75)
|
